Oncolytic adeno-immunotherapy modulates the immune system enabling CAR T-cells to cure pancreatic tumors
Rosewell Shaw et al. show that a previously developed immunotherapy strategy, coupling oncolytic adenoviral immunotherapy with clinically tested HER2-specific CAR T-cells, is effective against pancreatic ductal adenocarcinoma (PDAC). This combination therapy produces a curative response in both PDAC...
Guardado en:
Autores principales: | Amanda Rosewell Shaw, Caroline E. Porter, Tiffany Yip, Way-Champ Mah, Mary K. McKenna, Matthew Dysthe, Youngrock Jung, Robin Parihar, Malcolm K. Brenner, Masataka Suzuki |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/6c619b9e136441a696783c518011c56f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Adeno-associated virus capsid assembly is divergent and stochastic
por: Tobias P. Wörner, et al.
Publicado: (2021) -
Oncolytic virus-derived type I interferon restricts CAR T cell therapy
por: Laura Evgin, et al.
Publicado: (2020) - Oncolytic Virotherapy
-
Oncolytic Virotherapy
Publicado: (2016) -
Oligonucleotide conjugated multi-functional adeno-associated viruses
por: Dhruva Katrekar, et al.
Publicado: (2018)